Literature DB >> 35578282

A fatal case of disseminated nocardiosis due to Nocardia otitidiscaviarum resistant to trimethoprim-sulfamethoxazole: case report and literature review.

Mazin Barry1,2,3, Shahad AlShehri4, Ahlam Alguhani5, Mohammad Barry6, Ali Alhijji7,8, Khalifa Binkhamis9,8, Fahad Al-Majid7,8, Fatimah S Al-Shahrani7,8, Taim Muayqil8,10.   

Abstract

BACKGROUND: Disseminated nocardiosis still causes significant morbidity and mortality and is often caused by Nocardia asteroides, N. basiliensis, and N. farcinica and are often treated with trimethoprim-sulfamethoxazole (TMP-SMX). Nocardia otitidiscaviarum (N. otitidiscaviarum) rarely causes disseminated disease and resistance to TMP-SMX is even more rare. CASE
PRESENTATION: A 37-year-old woman with metastatic breast cancer and right ear deafness with recent occupational gardening and manipulating soil, presented to the hospital with first time seizure and multiple skin nodules. Magnetic resonance imaging (MRI) showed ring enhancing lesions, biopsy of the skin and brain lesions grew N. otitidiscaviarum. She was empirically treated with TMP-SMX and Imipenem-Cilastatin, however, almost three weeks into therapy, susceptibility results revealed it to be resistant to both antimicrobials, she was subsequently changed to Amikacin, Linezolid, Moxifloxacin, and Doxycycline but ultimately died.
CONCLUSIONS: This case report highlights the importance of suspecting a rare Nocardia species in patients at risk with proper occupational exposure, moreover, TMP-SMX resistance should be suspected with lack of clinical response, this may have important implications on clinical practice when facing similar infections.
© 2022. The Author(s).

Entities:  

Keywords:  Nocardia otitidiscaviarum; Nocardiosis; Trimethoprim–sulfamethoxazole (TMP–SMX)

Mesh:

Substances:

Year:  2022        PMID: 35578282      PMCID: PMC9112502          DOI: 10.1186/s12941-022-00511-9

Source DB:  PubMed          Journal:  Ann Clin Microbiol Antimicrob        ISSN: 1476-0711            Impact factor:   6.781


Background

Disseminated nocardiosis is a rare disease that can be fatal and is often attributed to the three more commonly known species: Nocardia asteroides, N. basiliensis, and N. farcinica [1]. N. otitidiscaviarum was first isolated from the mid-ear of a guinea pig and hence its name, it was then isolated from humans as well [2, 3]. Trimethoprim–sulfamethoxazole (TMP–SMX) or Linezolid are the backbone of therapy regimens for nocardiosis. However, a combination therapy is usually required. Resistance to TMP–SMX is rarely reported. We describe a case of an extensively disseminated infection with N. otitidiscaviarum, a species that was rarely described as a significant pathogen in the medical literature.

Case

A 37-year-old woman presented with a generalized tonic–clonic seizure that spontaneously aborted after three minutes with post-ictal incontinence. Over the preceding one month she had noticed multiple nodules under her skin on the right leg, and over her abdomen. They were mildly painful, eventually the overlying skin developed dark discoloration. There was no drainage, and she did not have similar skin lesions in the past. She is a known case of stage 4 invasive ductal carcinoma of the breast with metastasis to the liver, bone, and lungs that was diagnosed two years prior to the current presentation. She was recently on carboplatin/paclitaxel for a total of 8 weeks with the last dose given 3 weeks prior to this presentation. She has not been on corticosteroids in the preceding three months. Furthermore, over the past months prior to her current illness, she had been caring for domestic canaries and gardening frequently without the use of personal protective equipment nor gloves, reporting handling dirt and soil with her bare hands with frequent touching of her face. On arrival the patient’s vital signs were normal (Table 1), and her neurological examination was unremarkable. There were multiple nodules in the extensor area of the right leg and on the surface of her abdomen measuring 1 × 1 cm in size, they were firm, non-mobile with an erythematous base and overlying dark discoloration, they were mildly tender without any drainage (Fig. 1).
Table 1

Clinical and laboratory variables

Laboratory variableMeasurementsNormal valueClinical variableMeasurements
WBC9 × 109/L3.5–12.0 × 109/LGlasgow coma scale15/15
Haemoglobin125 g/L120–160 g/LTemperature37 °C
Haemaocrit %38%37–47%Blood pressure110/64 mmHg
Platelets144 × 109/L140–450 × 109/LRespiratory rate20 Breaths/minute
International normalized ratio (INR)0.93 s0.8–1.3 sHeart rate88 Beats/minute
Erythrocyte sedimentation rate (ESR)120 mm/h0–29 mm/hOxygen saturation99%
C-reactive protein2.9 mg/L< 10 mg/L
Creatinine55 µmol/L53–115 µmol/L
Fig. 1

Nodular skin lesion overlying patient’s abdomen (left) and leg (right)

Nodular skin lesion overlying patient’s abdomen (left) and leg (right) Blood results revealed elevated erythrocyte sedimentation rate (Table 1). Clinical and laboratory variables Computed tomography (CT) of the chest showed right lower lobe consolidation with cavity containing air-fluid level, with bibasilar atelectatic bands (Fig. 2).
Fig. 2

Axial CT chest with right lower lobe cavitary lesion containing air-fluid level (arrow)

Axial CT chest with right lower lobe cavitary lesion containing air-fluid level (arrow) CT brain showed left parietal–temporal hypodensities. Cerebrospinal fluid (CSF) analysis showed no signs of inflammation and microbiological evaluation including Mycobacterium tuberculosis PCR did not reveal any pathogen. Magnetic resonance imaging (MRI) of the Brain showed multiple ring enhancing lesions in the left frontoparietal region, bilateral frontal regions, right parietal lobe and vermis, while T2 weighted image showed cortical and subcortical cystic lesions (Fig. 3).
Fig. 3

MRI T2 weighted image of brain showing cortical and subcortical cystic lesions with surrounding vasogenic edema in the left parietal lobe (arrows)

MRI T2 weighted image of brain showing cortical and subcortical cystic lesions with surrounding vasogenic edema in the left parietal lobe (arrows) A left parietal mini-craniotomy was performed and frank pus was drained with necrotic tissue. The histopathology showed no evidence for malignancy (metastasis) but histological features consistent with brain abscess and no granulomas. A modified Kinyoun stain showed branching bacilli (Fig. 4). The skin lesion punch biopsy modified Kinyoun stain showed similar result.
Fig. 4

Brain tissue: modified Kinyoun stain with branching bacilli

Brain tissue: modified Kinyoun stain with branching bacilli Tissue samples from the patient’s brain and skin lesions were cultured onto different media including sheep blood agar, chocolate agar, MacConkey agar and Sabouraud Dextrose Agar (Saudi Prepared Media Laboratory Company Ltd, Riyadh, Saudi Arabia). Initial growth was observed from both samples after 2 days of incubation on blood, chocolate and Sabouraud agars. There was only one colony type observed, the isolate was found to be catalase positive, the colony Gram showed beaded branching Gram-positive bacilli, acid fast stain was negative, and modified Kinyoun stain was positive. The organism was identified using Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (bioMerieux, Marcy-l ’Etoile, France) with 99.9% confidence value as Nocardia otitidiscaviarum. This was done through an extraction process using the Vitek MS Mycobacterium/Nocardia kit (bioMerieux, Marcy-l ’Etoile, France). Susceptibility testing was referred out and performed using the Sensititre™ RAPMYCOI panel (Thermo Fisher Scientific, Massachusetts, United States) and interpreted using Clinical and Laboratory Standards Institute interpretive breakpoints (CLSI M24: Clinical and Laboratory Standards Institute standard M24—Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes). Upon presentation she was started on Imipenem-Cilastatin 500 mg IV every 6 h and trimethoprim–sulfamethoxazole (TMP–SMX) 15 mg/kg/day of TMP component IV divided every 8 h, on day 14 of hospital stay she developed a new skin lesion in the abdomen, Amikacin 30/kg/day IV was added. On day 22 of hospital stay, the susceptibility results returned from the outside referred lab showing TMP-SMX and Imipenem resistance (Table 2).
Table 2

Broth microdilution antibiotic susceptibility testing and interpretation based on CLSI M24

AntibioticMIC (μg/mL)Interpretation
Trimethoprim–sulfamethoxazole≥ 8/152Resistant
Linezolid4.0Sensitive
Ciprofloxacin≥ 4.0Resistant
Imipenem≥ 64.0Resistant
Moxifloxacin2.0Intermediate
Cefepime≥ 32.0Resistant
Cefoxitin128Resistant
Amoxicillin–Clavulanic acid≥ 64/32Resistant
Amikacin2.0Sensitive
Ceftriaxone16.0Intermediate
Doxycycline2.0Intermediate  
Minocycline2.0Intermediate
Tigecycline0.5Not applicable
Tobramycin≥ 16.0Resistant
Clarithromycin≥ 16.0Resistant
Broth microdilution antibiotic susceptibility testing and interpretation based on CLSI M24

Discussion and conclusion

In this report, we describe a rare fatal case of disseminated nocardiosis due to N. Otitidiscaviarum resistant to TMP–SMX in a lady with advanced cancer. The most common clinical presentation of nocardial disease is pulmonary due to inhalation of mycelial fragments or via contact with the bacteria by a cut or abraded skin which may lead to extrapulmonary dissemination [1]. In our case, the patient’s risk factor was gardening. N. otitidiscaviarum, formerly called N. caviae, was first reported in humans in the mid-1960s [2]. It was previously reported in 1924 after the organism was isolated from a guinea pigs middle ear [3]. Infections with Nocardia are being increasingly recognized, however, infections due to N. otitidiscaviarum are reported in only 0.3–2.9% of all Nocardia. infections and remains infrequently reported [4]. In one review only 10 cases of 347 patients infected with Nocardia. in the United States were identified as N. otitidiscaviarum [5]. In a Japanese report of more than 303 pathogenic Nocardia isolated from infected patients between 1992 and 2001, only 14 cases were due to N. otitidiscaviarum [6]. More recently, Chen Liu et al. described a fatal case of severe pneumonia due to N. otitidiscaviarum in an immunocompetent cotton farmer [7], while Ranjit Sah et al. reported successful treatment of a patient under steroid therapy with disseminated N. otitidiscaviarum [8]. Moreover, it was reported to cause disease in both immunocompetent and immunocompromised hosts in the forms of pulmonary, cutaneous, central nervous system and lymphocutaneous infections [4]. In nature, N otitidiscaviarum is found in soil, decomposing vegetation, and other organic matter, as well as in fresh and saltwater [9]. A survey of 504 soil samples in India revealed that N. otitidiscaviarum had a much lower prevalence compared to other Nocardia which may indicate the reason for its low incidence in clinical practice [10]. In addition, it was noted to be less pathogenic in humans when compared to other Nocardia. Being described as an opportunistic pathogen, individuals with weakened immune system, such as patients suffering from diabetes mellitus, chronic obstructive pulmonary disease, mixed connective tissue disorder, ulcerative colitis, cirrhosis, human immunodeficiency virus (HIV) infection, malignancies, those receiving long-term or large doses of corticosteroid therapy, and stem cell or solid organ transplant recipients are at higher risk for infections due to N. otitidiscaviarum  [11], similarly, our case had stage 4 invasive ductal carcinoma of the breast and was on chemotherapy for eight weeks with the last dose given three weeks before her presentation. In a review of the database for N. otitidiscaviarum, 25 cases had been reported between 1997 and 2018 [7, 12–30]. More than half of those cases were reported in immunocompromised patients. Prolonged use of corticosteroids was a major risk factor in the majority [12, 13, 16, 20, 21, 23, 30, 31]. In other cases, organ transplant recipients [32], endocrine disorders [26], HIV and rheumatic heart disease were identified as risk factors [18, 20, 25]. On the other spectrum, eight cases were reported in immunocompetent patients. Four of those were engaged in gardening or farming and were exposed to dust inhalation similarly to our patient [7, 15, 19, 22]. Only one case reported no underlying immunocompromised state nor any occupational risk factors like farming [13]. It may be challenging to diagnose such patients who present with many possible differential diagnoses. Conventional evaluation of specimens including wound drainage, skin and brain lesions biopsies, CSF analysis and cultures along with imaging studies, all remain the principal diagnostic methods. In the present report, the species was determined using MALDI-TOF MS. Although the gold standard for Nocardia species identification is molecular biology with amplification and sequencing of one or two gene(s) among rrs (i.e. the gene coding for 16 S rRNA), hsp65, secA1 and sodA, MALDI-TOF MS is increasingly being used for identifying Nocardia species. MALDI-TOF MS adequately identifies frequent species in 95–100% of cases, however for cases of a low identification score molecular biology-based identification remains important [33]. The isolate in the current study had a 99.9% confidence value, hence no molecular sequencing was performed. Most N. otitidiscaviarum isolates are reported to be resistant to beta-lactams while usually being susceptible to Amikacin, Fluoroquinolones [12, 34], and trimethoprim–sulfamethoxazole, hence, Sulfonamides remain the standard agents for treatment [12]. Meanwhile, some studies reported N. otitidiscaviarum susceptibility to Linezolid in-vitro; however, data from in-vivo studies are still lacking and the risk of haematological toxicity with prolonged Linezolid therapy is high, hindering its clinical use [35, 36]. A study that assessed 552 clinical isolates of Nocardia from six major laboratories in the USA, found sulfonamide resistance to be only 2%, which is lower than previously shown [37, 38]. The authors hypothesized that these discrepancies may be associated with difficulty in the laboratory interpretation of in vitro MICs for TMP-SMX and SMX and the lack of quality controls for Nocardia for these agents [39]. The isolate in the current study showed MIC of ≥ 8/152 for TMP/SMX respectively, which indicates it to be a realistic phenomenon. However, Imipenem resistance has been more commonly described [34]. Typical in-vitro antimicrobial susceptibility patterns of various Nocardia species indicates that N. otitidiscaviarum is usually susceptible to TMP–SMX (Table 3).
Table 3

Typical in-vitro antimicrobial susceptibility patterns of various Nocardia species (Adapted from Manual of clinical microbiology [40])

DrugN. abscessusN. brasiliensisN. brevicatena and N. paucivoransN. cyriacigeorgicaN. farcinicaN. nova complexN. otitidiscaviarumN. pseudobrasiliensisN. transvalensis complex
Amoxicillin–Clavulanic AcidSSSRRRR
AmikacinSSSSSSR
CeftriaxoneSSSRSRS
CiprofloxacinRRSRSSSS
ClarithromycinRRRRRSSR
GentamicinRRSR
ImipenemRRSSSRS
LinezolidSSSSSSSSS
MinocyclineSR
SulfamethoxazoleSSS
TobramycinRR

S susceptible, R Resistant

The optimal antimicrobial management for N. otitidiscaviarum is still not clearly defined, however, combined treatment is suggested for disseminated and severe disease. In our case, the isolated N. otitidiscaviarum was susceptible to Linezolid and Amikacin and was resistant to TMP-SMX, Ciprofloxacin, Imipenem, Cefepime, Cefoxitin, Amoxicillin-Clavulanic acid, Clarithromycin and Tobramycin. Seven cases were similarly reported with resistance to TMP-SMX [17, 19, 21, 24, 28, 30] with four cases reported in immunocompetent patients [17, 19, 24], and one infecting a farmer [19], details of these studies are described in Table 4

Typical in-vitro antimicrobial susceptibility patterns of various Nocardia species (Adapted from Manual of clinical microbiology [40]) S susceptible, R Resistant The optimal antimicrobial management for N. otitidiscaviarum is still not clearly defined, however, combined treatment is suggested for disseminated and severe disease. In our case, the isolated N. otitidiscaviarum was susceptible to Linezolid and Amikacin and was resistant to TMP-SMX, Ciprofloxacin, Imipenem, Cefepime, Cefoxitin, Amoxicillin-Clavulanic acid, Clarithromycin and Tobramycin. Seven cases were similarly reported with resistance to TMP-SMX [17, 19, 21, 24, 28, 30] with four cases reported in immunocompetent patients [17, 19, 24], and one infecting a farmer [19], details of these studies are described in Table 4
Table 4

Case studies of N. otitidiscaviarum resistant to TMP-SMX

ReferencesYearsAge/genderImmune Status Drug SusceptibilityTreatmentOutcome
Matsu et al.  [19]200074MImmunocompetent (Farmer)Resistant to: TMP-SMX, Penicillin, Piperacillin, Imipenem, Ceftazidime. Susceptible to: Amikacin, Minocycline, ClarithromycinTMP-SMX à Clarithromycin + AmikacinRecovered
Yoshida et al. [30]200469MOn Corticosteroid therapyResistant to: Ampicillin, Piperacillin, Cefazolin, Imipenem, minocycline, Vancomycin, TMP-SMX, Erythromycin. Susceptible to: Levofloxacin, Gentamicin and LevofloxacinImipenem + TMP-SMX à TMP-SMX + GentamicinRecovered
Mahgoub et al. [17]201641FImmunocompetentResistant to: Azithromycin, Ceftazidime, Penicillin, Rifampicin and TMP-SMX. Susceptible to: Amikacin, Ciprofloxacin, Meropenem and StreptomycinTMP-SMX + Amikacin + Imipenem à Ceftriaxone + Amikacin + CiprofloxacinRecovered
Candel et al. [13]201779MOn Corticosteroid therapyResistant to: TMP-SMX. Susceptible to Aminoglycosides, Beta-lactams and CarbapenemLevofloxacin + Vancomycin + TobramycinDied
Princess et al.  [21]201851FOn Corticosteroid therapyResistant to: TMP-SMX, Amoxicillin, Clavulanate. Susceptible to: Amikacin, Ciprofloxacin, Linezolid, Imipenem and CeftriaxoneAzithromycin + Doxycycline à TMP-SMX + ImipenemDied
Saksena et al. [24]202074MImmunocompetentResistant to: Ampicillin, Amoxicillin-Clavulanate, Erythromycin, TMP-SMX and imipenem. SusceptibleTo: Amikacin, Linezolid, Ciprofloxacin, and GentamicinAmoxicillin-Clavulanate + Azithromycin à TMP-SMXDied
Saksena et al. [24]202074FImmunocompetentResistant to: Ampicillin, Amoxicillin-Clavulanate, Erythromycin, TMP-SMX and imipenem. Susceptible to: Amikacin, Linezolid, Ciprofloxacin, and GentamicinMeropenem + Colistin à TMP-SMX addedDied

M, male; F, female; TMP-SMX, trimethoprim–sulfamethoxazole; GCS, Glasgow coma scale

Case studies of N. otitidiscaviarum resistant to TMP-SMX M, male; F, female; TMP-SMX, trimethoprim–sulfamethoxazole; GCS, Glasgow coma scale Similarly, in our case combined drug therapy with Imipenem and TMP-SMX were used for a total of 22 days until the susceptibility result showed resistance to both agents and treatment with Linezolid, Ceftriaxone, moxifloxacin, doxycycline was used in addition to Amikacin that was added earlier due to the appearance of new skin lesions. The delay in obtaining susceptibility results from the outside lab clearly had a negative impact on patient outcome, such cases would advocate for wider availability of such testing and higher turnaround time. Mortality due to disseminated Nocardiosis is high, therefore early diagnosis and initiation of therapy are of vital importance in Nocardial infections. In our case, the patient was started on empirical treatment for Nocardiosis that was later adjusted according to the susceptibility results, however, the delay in administering proper antimicrobials and her pre-existing advanced malignancy may have attributed to her mortality. In conclusion, N. otitidiscaviarum infection though rare may have considerable mortality; early diagnosis and susceptibility testing are crucial in avoiding similar devastating outcomes. In addition, surveillance for emerging TMP-SMX resistance should be closely monitored.
  39 in total

1.  [Pulmonary Nocardia otitidis-caviarum infection in a patient with Cushing's disease].

Authors:  A Sudou; T Hashimoto; H Nakamura; H Yagyuu; G Sarashina; E Hatao; F Tuchida; H Adachi; K Kishi; T Matuoka
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2001-03

Review 2.  Nocardiosis.

Authors:  P I Lerner
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

Review 3.  How do I manage nocardiosis?

Authors:  Ili Margalit; David Lebeaux; Ori Tishler; Elad Goldberg; Jihad Bishara; Dafna Yahav; Julien Coussement
Journal:  Clin Microbiol Infect       Date:  2021-01-05       Impact factor: 8.067

4.  Pulmonary nocardiosis caused by Nocardia otitidiscaviarum in an adult asthmatic female patient: The presence of acid-fast branching filaments is always significant.

Authors:  A Mahgoub; S A Gumaa; M R P Joseph; M S Saleh; A H A Elsheikh; A I Elkhalifa; E Elhaj; R R M Salih; M E Hamid
Journal:  S Afr Med J       Date:  2016-12-21

5.  Clinical experience with linezolid for the treatment of nocardia infection.

Authors:  Edina H Moylett; Susan E Pacheco; Barbara A Brown-Elliott; Tracy R Perry; E Stephen Buescher; Mary C Birmingham; Jerome J Schentag; Joseph F Gimbel; Aaron Apodaca; Margot A Schwartz; Robert M Rakita; Richard J Wallace
Journal:  Clin Infect Dis       Date:  2003-01-13       Impact factor: 9.079

Review 6.  Linezolid for the treatment of Nocardia spp. infections.

Authors:  Tomasz Z Jodlowski; Igor Melnychuk; John Conry
Journal:  Ann Pharmacother       Date:  2007-09-04       Impact factor: 3.154

Review 7.  Fatal pulmonary infection by trimethoprim-sulfamethoxazole resistant Nocardia otitidiscaviarum: report of two cases and review.

Authors:  Rushika Saksena; Dabet Rynga; Santosh Rajan; Rajni Gaind; Reetika Dawar; Raman Sardana; Manas Kamal Sen; Jagdish Chandra Suri
Journal:  J Infect Dev Ctries       Date:  2020-02-29       Impact factor: 0.968

Review 8.  Nocardiosis: updated clinical review and experience at a tertiary center.

Authors:  J Ambrosioni; D Lew; J Garbino
Journal:  Infection       Date:  2010-03-20       Impact factor: 7.455

9.  Pulmonary Nocardiosis and Scrub Typhus in an Immunocompromised Host.

Authors:  Isabella Princess; R Ebenezer; Nagarajan Ramakrishnan; S Nandini
Journal:  J Glob Infect Dis       Date:  2018 Apr-Jun

10.  A fatal case of Nocardia otitidiscaviarum pulmonary infection and brain abscess: taxonomic characterization by molecular techniques.

Authors:  Ana Isabel Pelaez; Maria del Mar Garcia-Suarez; Angel Manteca; Ovidio Melon; Carlos Aranaz; Rafael Cimadevilla; Francisco Javier Mendez; Fernando Vazquez
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-14       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.